Insights+: COVID-19 Healthcare News Monthly Updates – April 2020

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it The outbreak of the respiratory disease was first detected in Wuhan City, Hubei Province, China in Dec 2019 PharmaShots is keeping a track of all of the important updates in the Lifesciences sector, where…

BySenior EditorJanuary 5, 2020

TOP 20

Top Biopharma Deal Terminations of 2018-2019 by Total Value Received

The biopharma industry saw a significant increase in the number of deal terminations in the last two years. Clinical and regulatory results- change in control limitations- and strategic reprioritizations were among the most common reasons for deal termination. We used the DealForma database to track partnership terminations announced in 2018 and 2019. We compiled a list of…

ByPrince GiriJanuary 3, 2020

TOP 20

Top 20 Biopharma Acquisitions of 2018 Based on the Total Deal Value

Biopharma acquisition activity in 2018 shows a significant increase over the previous year. Takeda proved to be on top with the acquisition of Shire among the top 20 acquisitions with a total deal value of $57.17B strengthening its capabilities in gastroenterology- neuroscience- oncology- rare diseases- and plasma-derived therapies. This article is based on the 2018…

ByPrince GiriSeptember 27, 2019

INSIGHTS+

PharmaShots’ Key Highlights of Third Quarter 2019

The third quarter of 2019 has ended with major acquisitions in the pharma and biotech industry along with multiple approvals. Starting with the latest acquisition where Biocon Biologics acquires Pfizer's Research Facility for expansion of its R&D footprints with the acceleration of the development of its biosimilars from lab to pilot scale. Previously, Amgen acquired…

BySenior EditorSeptember 7, 2019

TOP 20

Top 20 Life Sciences Deals of 2018 Based on Total Deal Value

Healthcare- pharmaceutical- and biotech companies are gearing up to tap new markets as they look to consolidate their positions after a spate of mergers & acquisitions and licensing partnerships in 2018. The highest valued deal proved to be of Takeda's acquisition of Shire for $57B with the focus on global R&D- its robust and modality-diverse…

ByPrince GiriAugust 23, 2019

INSIGHTS+

PharmaShots’ Key Highlights of First Quarter 2019

The first quarter of 2019 has marked with major events in the pharma & biotech industries. We have gathered the key highlights of the quarter, which was starting with the blockbuster news, where Celgene had acquired BMS for $74B. Moving to the next news, acquisition of Loxo Oncology for $8B, in addition to Spark Therapeutics…

BySenior EditorAugust 4, 2019

TOP 20

Top 10 Oncology Companies By 2018 Revenue

The Pharma companies focusing on oncology has been emerging in market with greater needs of people suffering from Cancer. The sales of oncology drugs gradually increasing with diseases. The top oncology companies are now developing more advanced- effective- and tolerable drugs to improve treatment outcomes and the patient experience. Roche proved to be on top…

ByPrince GiriMay 31, 2019

TOP 20

Top 20 BioPharma Companies based on 2018 Total Revenue

The global pharma companies have been advancing their pipelines with emerging needs of patients. Pharma companies are also focusing on diagnostics & devices- which were emerged as one of major revenue generator in 2018- with the development of new products and devices. The year 2018 also proved to be a record with approval of 55…

ByPrince GiriMay 1, 2019

Insights+: COVID-19 Healthcare News Monthly Updates – April 2020

Top Biopharma Deal Terminations of 2018-2019 by Total Value Received

Top 20 Biopharma Acquisitions of 2018 Based on the Total Deal Value

PharmaShots’ Key Highlights of Third Quarter 2019

Top 20 Life Sciences Deals of 2018 Based on Total Deal Value

PharmaShots’ Key Highlights of First Quarter 2019

Top 10 Oncology Companies By 2018 Revenue

Top 20 BioPharma Companies based on 2018 Total Revenue

Contact US

FOLLOW US